Novel Agents Ease Chemotherapy Burden in ALL, But Treating Older Patients Remains a Challenge

Christin Melton, ELS
Published: Tuesday, Mar 19, 2019
Mark R. Litzow, MD
Mark R. Litzow, MD
Immune-based approaches have revolutionized the treatment of acute lymphoblastic lymphoma (ALL), especially for patients unable to tolerate multiagent chemotherapy. Now, investigators are looking forward to seeing these agents move into frontline settings, perhaps leading to chemotherapy-free approaches.

program.

New Agents for Philadelphia-Negative ALL

The first element of risk stratification, according to Bijal D. Shah, MD, is determining whether patients are fit enough to receive intensive chemotherapy. Because age is often viewed as a barometer of fitness, fit elderly patients are frequently denied highly toxic, yet potentially curative, therapies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x